683 Capital Management, LLC Provention Bio, Inc. Transaction History

683 Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$6.7 - $24.21 $1.84 Million - $6.66 Million	275,000 Added 50.0%	825,000 $19.9 Million
Q4 2022 Feb 14, 2023	BUY	$4.52 - $10.57 $2.49 Million - $5.81 Million	550,000 New	550,000 $5.81 Million
Q4 2021 Feb 14, 2022	SELL	$5.59 - $7.39 $1.11 Million - $1.47 Million	-198,429 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$5.66 - $8.33 $566,000 - $833,000	-100,000 Reduced 33.51%	198,429 $1.27 Million
Q2 2021 Aug 16, 2021	SELL	$6.71 - $11.04 $2.22 Million - $3.66 Million	-331,571 Reduced 52.63%	298,429 $2.52 Million
Q1 2021 May 17, 2021	SELL	$10.12 - $19.45 $2.32 Million - $4.46 Million	-229,314 Reduced 26.69%	630,000 $6.61 Million
Q3 2020 Nov 16, 2020	BUY	$10.34 - $15.2 $2.68 Million - $3.94 Million	259,314 Added 43.22%	859,314 $11 Million
Q2 2020 Aug 14, 2020	BUY	$7.81 - $17.0 $4.69 Million - $10.2 Million	600,000 New	600,000 $8.47 Million
Q1 2020 May 15, 2020	SELL	$5.42 - $17.75 $84,595 - $277,042	-15,608 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$5.84 - $14.9 $91,150 - $232,559	15,608 New	15,608 $233,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.